Successful Reduced-Intensity Conditioning Allogeneic HSCT For HIV-Related Primary Effusion Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 601-602

  Bryant, Adam ^a   Milliken, Sam ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZITHROMYCIN; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GEMCITABINE; HEPARIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MELPHALAN; METHOTREXATE; NAVELBINE; NORFLOXACIN; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; TENOFOVIR; URSODEOXYCHOLIC ACID; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASCITES; ASCITES FLUID; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS COMPLICATION; LETTER; MALE; MALE HOMOSEXUAL; MYELOABLATIVE CONDITIONING; PNEUMOCYSTOSIS; PRIMARY EFFUSION LYMPHOMA; REDUCED INTENSITY CONDITIONING; VEIN OCCLUSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, PRIMARY EFFUSION; MALE; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 41849134620     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.01.010     Document Type: Letter

References (11)

1. Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 17 (2003) 785-820
2. Boulanger E., Gerard L., Gabarre J., et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23 (2005) 4372-4380
3. Krishnan A., Molina A., Zaia J., et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105 (2005) 874-878
4. Giri N., Vowels M.R., and Ziegler J.B. Failure of allogeneic bone marrow transplantation to benefit HIV infection. J Paediatr Child Health 28 (1992) 331-333
5. Schlegel P., Beatty P., Halvorsen R., and McCune J. Successful allogeneic bone marrow transplant in an HIV-1-positive man with chronic myelogenous leukemia. J Acquir Immune Defic Syndr 24 (2000) 289-290
6. Torlontano G., Di Bartolomeo P., Di Girolamo G., et al. AIDS-related complex treated by antiviral drugs and allogeneic bone marrow transplantation following conditioning protocol with busulphan, cyclophosphamide and cyclosporin. Haematologica 77 (1992) 287-290
7. Kang E.M., de Witte M., Malech H., et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 99 (2002) 698-701
8. Wolf T., Rickerts V., Staszewski S., et al. First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica 92 (2007) e56-e58
9. Wilson W.H., Bryant G., Bates S., et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11 (1993) 1573-1582
10. Spencer A., Catalano J., Grigg A., et al. A stratified risk-adapted approach to lymphoma salvage in an outpatient setting. ASH Annu Meet Abstr 104 (2004) 4597a
11. Gaspard M.H., Maraninchi D., Stoppa A.M., et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 22 (1988) 256-262